Last Updated: November 18, 2026

Details for Patent: 7,332,183

« Back to Dashboard


Which drugs does patent 7,332,183 protect, and when does it expire?

Patent 7,332,183 protects TREXIMET and is included in one NDA.

Protection for TREXIMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 7,332,183
Title:Multilayer dosage forms containing NSAIDs and triptans
Abstract:The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.
Inventor(s):John R. Plachetka, Venkata Markandeya Kothapalli, Donna L. Gilbert
Assignee: Nuvo Pharmaceuticals (ireland) Designated Activity Co
Application Number:US10/741,592
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,332,183
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Drug Patent 7,332,183: Claim Scope, Treximet Patent Landscape, and Generic Entry Risk

U.S. Patent No. 7,332,183 protects a specific physical architecture for combining naproxen or another NSAID with a triptan in one oral tablet. Its central limitation is not merely the combination of active ingredients. The patent requires substantially separate layers arranged side by side so that dissolution of the NSAID occurs independently from dissolution of the triptan.

The patent was assigned to Pozen Inc. and relates directly to the formulation concept used for Treximet, the fixed-dose combination of sumatriptan succinate and naproxen sodium. The patent’s ordinary 20-year term ran from the relevant U.S. filing date and has expired, subject to any applicable patent-term adjustment or regulatory extension shown in USPTO and FDA records. The patent therefore presents historical formulation significance but does not, by itself, create a current barrier to generic entry.

What does U.S. Patent 7,332,183 protect?

The patent protects a multilayer pharmaceutical tablet containing two pharmacologically different components:

Component Claimed requirement
Triptan Substantially all triptan must be in a first layer
Naproxen or NSAID Substantially all naproxen or NSAID must be in a separate second layer
Arrangement The layers must be side by side
Dissolution Naproxen or NSAID dissolution must occur independently of triptan dissolution
Dosage form Tablet, including a bilayer tablet or a coated multilayer tablet
Therapeutic use Treatment of headache, including migraine headache

Claim 1 is the principal composition claim. It requires both chemical content and physical structure. A tablet containing sumatriptan and naproxen in a homogeneous blend does not satisfy the literal architecture of claim 1 because the actives are not substantially segregated into separate layers.

Claim 19 broadens the NSAID component beyond naproxen. It refers to an “NSALD,” while the dissolution limitation refers to an “NSAID.” The apparent terminology inconsistency is likely intended to cover a nonsteroidal anti-inflammatory drug. The ambiguity could have affected claim construction in litigation, but the patent’s expiration now removes its practical enforcement significance.

How do the independent claims differ?

The patent has three principal independent claim groups.

Claim 1: Multilayer tablet

Claim 1 requires:

  1. A pharmaceutical tablet.
  2. Naproxen and a triptan.
  3. Substantially all triptan in one layer.
  4. Substantially all naproxen in a separate layer.
  5. Side-by-side arrangement.
  6. Independent dissolution behavior.

The independent-dissolution requirement is important. A two-layer tablet could still fall outside the claim if the layers are arranged or formulated so that the naproxen and triptan dissolve as a single interacting mass.

Claim 13: Method of treating headache

Claim 13 covers administering a tablet within claims 1 through 8 at a dosage effective to alleviate headache pain. Claim 14 narrows the indication to migraine headache.

These method claims depend on the underlying multilayer formulation. They do not independently protect the use of sumatriptan or naproxen in migraine treatment without the specified tablet structure.

Claim 19: Multilayer tablet containing an NSAID

Claim 19 covers a tablet containing an NSALD or NSAID and a triptan, with the same separated-layer and independent-dissolution requirements.

This claim may reach products containing NSAIDs other than naproxen, although the terminology defect and the specification’s disclosed embodiments would be relevant to claim construction.

Claim 20: Rapid-release method

Claim 20 covers administration of the tablet of claim 4 or claim 5, with the requirement that dissolution of sumatriptan and naproxen is faster than dissolution from a tablet in which the ingredients are in physical admixture.

This is a comparative performance claim. It creates evidentiary issues because infringement may require testing the accused product against a comparison formulation. The claim is narrower than a simple claim to a sumatriptan-naproxen combination.

What formulations are protected by U.S. Patent 7,332,183?

The patent protects several structural variations of the same multilayer concept.

Claim Protected feature
1 Naproxen and triptan in separate side-by-side layers
2 Naproxen sodium at 200-600 mg
3 Specific triptan group
4 Sumatriptan
5 Sumatriptan succinate at 25-100 mg
6 Layers juxtaposed symmetrically along a single planar surface
7 Layers directly contacting at the planar surface
8 At least one additional layer separating the principal layers
9 Bilayer dosage form
10 Coating surrounding both layers
11-12 Sumatriptan and sumatriptan succinate subcombinations
19 NSAID and triptan multilayer tablet
20 Comparative rapid-dissolution method

Claims 6 and 7 describe a conventional bilayer tablet in which each active is concentrated on one side of a planar interface. Claim 8 extends the concept to a multilayer structure in which an intermediate layer separates the active-containing layers.

The coating in claim 10 does not change the principal requirement that the active ingredients remain in separate layers. A conventional film coating surrounding the entire tablet can therefore fall within the claim if the internal architecture satisfies claim 1.

What are the dosage and active-ingredient limitations?

The most commercially relevant embodiment is:

  • Sumatriptan succinate: 25 mg to 100 mg.
  • Naproxen sodium: 200 mg to 600 mg.
  • Separate layers.
  • Side-by-side tablet configuration.
  • Use for acute migraine treatment.

Treximet is marketed as a fixed-dose combination containing 85 mg of sumatriptan base, supplied as sumatriptan succinate, and 500 mg of naproxen sodium. That dosage falls within claims 2, 4, and 5.

The patent does not require a particular ratio between the two actives, tablet weight, excipient system, manufacturing equipment, coating composition, dissolution medium, or release specification, except where those characteristics are necessary to satisfy the independent-dissolution language.

How does the patent distinguish a bilayer tablet from a physical admixture?

The distinction is structural and functional.

A physical-admixture tablet distributes sumatriptan and naproxen throughout a common blend before compression. The patented design places the components into separate tablet regions. The specification’s technical rationale is that the actives can have different dissolution characteristics and may interact adversely when mixed.

A product is more likely to satisfy the claims when:

  • Sumatriptan is concentrated in one discrete layer.
  • Naproxen sodium is concentrated in another discrete layer.
  • The layers have a visible or manufacturing-defined planar interface.
  • Dissolution testing demonstrates distinct or independent release behavior.
  • The tablet is compressed as a bilayer or multilayer unit.

A product is less likely to satisfy the claims when:

  • Both actives are uniformly dispersed throughout one matrix.
  • The tablet is a conventional single-layer direct-compression tablet.
  • The manufacturer uses separate granulations but combines them before final compression.
  • The formulation lacks evidence of independent dissolution.

“Substantially all” does not require absolute exclusion of the other active from each layer. Minor migration, residual carryover, or analytical detection below a material threshold may not defeat infringement. The precise threshold would depend on claim construction, the specification, prosecution history, and technical evidence.

What is the FDA and Orange Book status of the patent?

Treximet was approved by the FDA under NDA 021881. The product contains sumatriptan and naproxen sodium and is indicated for the acute treatment of migraine attacks with or without aura in adults (FDA, 2024).

The FDA Orange Book historically listed U.S. Patent No. 7,332,183 for Treximet. Orange Book listing is relevant to ANDA certification and patent-notice procedures, but it does not extend a patent’s substantive term. Once the listed patent expires or is delisted, the patent no longer provides an active Orange Book barrier to approval.

Regulatory item Status
Reference product Treximet
Active ingredients Sumatriptan succinate and naproxen sodium
FDA application NDA 021881
Regulatory sponsor history Pozen, GlaxoSmithKline, later commercial successors
Patent relevance Formulation and tablet architecture
Current patent barrier from U.S. 7,332,183 Expired based on its statutory patent term

The FDA’s regulatory exclusivity for the original product is separate from patent protection. New-drug exclusivity periods do not revive an expired formulation patent.

When did U.S. Patent 7,332,183 expire?

U.S. Patent 7,332,183 was granted on February 19, 2008. Its U.S. application was filed on October 31, 2003, and the patent’s ordinary 20-year term was therefore tied to the 2003 filing date, subject to patent-term adjustment and any applicable extension shown in official records (USPTO, 2008).

The commonly cited expiration date for the patent is October 31, 2023. Patent-term adjustment, terminal disclaimers, continuation relationships, or a regulatory patent-term extension would need to be confirmed from the USPTO patent record and FDA Orange Book entry for the specific patent.

Because the patent has reached the end of its ordinary term, claims 1-20 are no longer enforceable against commercial products solely on the basis of this patent.

What Paragraph IV challenges affected Treximet?

Generic applicants seeking approval before expiration of Orange Book-listed patents could file Paragraph IV certifications under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed (21 U.S.C. § 355(j)(2)(A)(vii)(IV)).

For Treximet, generic applicants faced several potential certification targets:

  • The core combination patent.
  • Formulation and manufacturing patents.
  • Method-of-use patents.
  • Later patents directed to dose, release profile, or tablet construction.

A Paragraph IV challenge to U.S. 7,332,183 would likely have focused on:

  1. Whether a claimed product used the required side-by-side layers.
  2. Whether substantially all of each active was confined to a separate layer.
  3. Whether dissolution of the two actives was independent.
  4. Whether the claims were anticipated or obvious over bilayer-tablet and migraine-combination prior art.
  5. Whether claim 20’s comparative dissolution limitation was definite and enabled.

The 30-month stay available under Hatch-Waxman applies to timely patent litigation after notice of a Paragraph IV certification. It does not apply after the relevant patent has expired.

Which companies challenged or competed against Treximet?

The commercial competitive field included both branded and generic manufacturers.

Company or product category Competitive relevance
Pozen Inc. Original innovator and formulation patent holder
GlaxoSmithKline Commercialization partner for Treximet
Pernix Therapeutics Later holder of Treximet commercial rights or assets
Currax Pharmaceuticals Later commercial owner of Treximet
Teva Generic and authorized-generic migraine competitor
Dr. Reddy’s Laboratories Generic sumatriptan-naproxen competitor
Other ANDA sponsors Potential entrants after patent and exclusivity barriers declined

Generic competition could avoid claim 1 by using a non-layered formulation, challenging the patent’s validity, waiting for expiration, or relying on a formulation that does not meet the independent-dissolution limitation.

How strong was the patent estate for Treximet?

U.S. 7,332,183 was technically meaningful but commercially narrow compared with a patent covering the active ingredients themselves.

Strengths

  • It covered the commercially relevant combination of sumatriptan and naproxen.
  • It protected a specific bilayer architecture.
  • Claims 2, 4, and 5 mapped closely to the marketed active ingredients and dose ranges.
  • The claims included both composition and method-of-treatment coverage.
  • The patent addressed a formulation problem that could support non-obviousness arguments.

Weaknesses

  • The patent did not cover sumatriptan or naproxen individually.
  • It did not necessarily cover a homogeneous single-layer tablet.
  • “Substantially all” created potential factual disputes.
  • “Independent” dissolution required technical testing and claim construction.
  • The claim 19 NSALD/NSAID terminology created interpretive risk.
  • Generic applicants could design around the multilayer structure.
  • Expiration eliminated current enforcement value.

The estate’s practical protection depended more on the combined effect of several patents than on 7,332,183 alone. Later patents could have protected other aspects of Treximet, but they would require separate analysis of their claims, Orange Book status, prosecution history, and expiration dates.

What generic launch scenarios existed?

Three launch paths were commercially available.

Design-around launch

A generic manufacturer could formulate sumatriptan and naproxen in a single physical admixture or another structure outside the multilayer claims. The principal risk would shift to other patents and to regulatory requirements for pharmaceutical equivalence.

Paragraph IV launch

An ANDA sponsor could challenge the patent before expiry and seek a commercial launch after the statutory stay period or following a favorable litigation outcome. The sponsor would need to address both the formulation patent and any later-listed patents.

Post-expiration launch

After expiration of U.S. 7,332,183, a generic could use a bilayer structure without infringing this patent, provided no other unexpired patent covered the product or its use.

What manufacturing and intellectual-property barriers remain?

The patent’s manufacturing concept requires controlled segregation of active ingredients during granulation, feeding, compression, and coating. Important manufacturing issues include:

  • Separate powder-flow properties for each layer.
  • Weight control for each active-containing layer.
  • Prevention of cross-contamination at the interface.
  • Consistent tablet hardness across layers.
  • Control of layer adhesion and delamination.
  • Independent dissolution performance.
  • Stability of sumatriptan succinate and naproxen sodium in the finished tablet.

Those manufacturing challenges are not, by themselves, enforceable patent rights after expiration. They can still create development cost, process-validation burdens, and quality-control requirements.

How does U.S. 7,332,183 compare with a conventional fixed-dose migraine tablet?

Attribute Patented multilayer tablet Conventional admixture tablet
Active distribution Separate layers Common blend
Dissolution design Independent release behavior Shared matrix behavior
Manufacturing Sequential or multilayer compression Single blending and compression process
Claim 1 exposure Potentially within claim scope Generally outside literal layer limitation
Development complexity Higher Lower
Patent workaround Limited by structural design Potential design-around route
Commercial purpose Coordinate two active ingredients Combine ingredients without spatial separation

Key Takeaways

  • U.S. Patent 7,332,183 protects a multilayer tablet containing naproxen or an NSAID and a triptan.
  • The key limitations are separate layers, side-by-side arrangement, substantial segregation of the actives, and independent dissolution.
  • The most commercially relevant embodiment is Treximet, containing 85 mg sumatriptan base and 500 mg naproxen sodium.
  • Claims 4 and 5 specifically target sumatriptan and sumatriptan succinate dosage ranges.
  • Claims 13-18 cover treatment of headache and migraine using the claimed tablets.
  • Claim 20 adds a comparative rapid-dissolution limitation.
  • The patent’s ordinary term expired in 2023, subject to official confirmation of any patent-term adjustment or extension.
  • The patent no longer independently blocks generic entry.
  • Generic manufacturers could have pursued Paragraph IV challenges, formulation design-arounds, or post-expiration launches.
  • Current Treximet risk must be assessed against the complete Orange Book and patent-family record, not U.S. 7,332,183 alone.

Frequently Asked Questions

Does U.S. Patent 7,332,183 cover Treximet itself?

Yes. The patent claims a formulation architecture consistent with Treximet, but it does not own the sumatriptan-naproxen active-ingredient combination in every dosage form.

Can a single-layer sumatriptan-naproxen tablet infringe claim 1?

Generally, not literally, because claim 1 requires separate first and second layers. Other patents, regulatory requirements, or equivalent-structure arguments could still be relevant.

Does the patent cover naproxen without naproxen sodium?

Claim 1 refers to naproxen broadly, while claim 2 specifically narrows the formulation to naproxen sodium at 200-600 mg. The scope depends on the particular claim asserted.

Is independent dissolution required for infringement?

Yes. The claim expressly requires dissolution of naproxen or the NSAID independently of dissolution of the triptan. Structural separation alone may not resolve every infringement issue.

Can a generic manufacturer use the same bilayer design now?

The expired patent no longer prevents that design by itself. A generic manufacturer must still evaluate any unexpired patents, regulatory requirements, trade secrets, and other intellectual-property rights affecting Treximet or its approved generic equivalent.

References

  1. Food and Drug Administration. (2024). Drugs@FDA: Treximet, NDA 021881. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  3. United States Congress. (2024). 21 U.S.C. § 355: New drugs.

  4. United States Congress. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

  5. United States Patent and Trademark Office. (2008). U.S. Patent No. 7,332,183, Multilayer pharmaceutical tablet. Washington, DC.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,332,183

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Azurity TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Azurity TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,332,183

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 546134 ⤷  Start Trial
Australia 2003303631 ⤷  Start Trial
Canada 2509023 ⤷  Start Trial
Cyprus 1112640 ⤷  Start Trial
Denmark 1575566 ⤷  Start Trial
European Patent Office 1575566 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.